Glaxo looking into Botox marketing tactics in China

UK-based drug maker GlaxoSmithKline (Glaxo; GSK.NYSE, GSK.LON) has launched an investigation into allegations that members of its China sales team bribed doctors with cash and perks to prescribe Botox, The Wall Street Journal reported. The company targeted 48 doctors with payments ranging between US$245 to US$490 for achieving sales targets, according to documents and emails reviewed by the Journal. Sales personnel were reportedly ordered by local managers to conceal evidence of their wrongdoing by using private emails. The news comes in addition to a broader probe into bribery allegations at the company.